Intestinal Autoimmunity Possibly Linked to ADT

ADT for prostate cancer may be associated with a reduced risk of inflammatory bowel disease.
ADT for prostate cancer may be associated with a reduced risk of inflammatory bowel disease.

Androgen deprivation therapy (ADT) for prostate cancer may be associated with a reduced risk of inflammatory bowel disease (IBD), according a recent report in the American Journal of Epidemiology (2016;184:15-22).

In a study of 31842 men newly diagnosed with prostate cancer, Laurent Azoulay, MD, of Jewish General Hospital in Montreal, and colleagues found men exposed to ADT had a significant 48% decreased risk of ulcerative colitis and a non-significant 62% decreased risk of Crohn's disease.

“These findings indicate that the use of ADT may be associated with intestinal autoimmunity,” the researchers concluded.

Continue Reading Below


Loading links....
You must be a registered member of Renal and Urology News to post a comment.

Sign up for free e-Newsletters